Group 1 - The new drug directory will be implemented in the province starting January 1, 2026, aiming to enhance the multi-level medical security system and include more effective and new drugs in the coverage [1] - Traditional Chinese medicine pieces will be managed under Class A, while the personal out-of-pocket ratio for regular Class B drugs (excluding negotiated drugs) will generally not exceed 10% [1] - For negotiated drugs, the personal out-of-pocket ratio for cancer treatment Western medicines will be 20%, while other drugs will be determined by each planning area, with a maximum of 20% [1] Group 2 - The commercial insurance innovative drug directory will be updated alongside the medical insurance directory, with the management of drugs in this directory following the principles of negotiated drugs [2] - Drugs in the commercial insurance innovative drug directory will not be covered by the medical insurance fund and will not be included in the basic medical insurance self-payment rate indicators [2] - Local medical insurance departments will promote the development of inclusive commercial health insurance and support the design of new products based on the commercial insurance innovative drug directory [2]

Core Viewpoint - The Commercial Health Insurance Innovative Drug Directory aims to provide a list of high-value innovative drugs that exceed basic medical insurance coverage, effective from January 1, 2026 [1][2]. Group 1: Overview of the Innovative Drug Directory - The directory includes 19 drugs focusing on three key areas: high-priced cancer treatments (5 Car-T cell therapy drugs), rare disease medications, and new targeted therapies for severe cancers [1]. - The directory is intended for reference by commercial health insurance and medical mutual aid systems, highlighting the importance of these drugs for patients with limited treatment options [1]. Group 2: Policy Implications - Drugs listed in the directory are not eligible for reimbursement under basic medical insurance, but the National Healthcare Security Administration has implemented a "three exclusions" policy to facilitate their use in hospitals [2]. - This policy alleviates concerns for hospitals regarding the use of innovative drugs, allowing for direct prescription and reimbursement through commercial insurance, thus bypassing previous complexities [2]. Group 3: Insurance Product Adaptation - Some commercial insurance products, such as certain惠民保 plans, have begun to incorporate drugs from the directory, offering increased reimbursement rates for hospital use of these drugs [2]. - Insurance companies are currently assessing how to integrate the directory's drugs into existing medical insurance products, with some already including specific innovative drugs as optional or mandatory coverage [3]. Group 4: Consumer Guidance - Consumers are advised to carefully review insurance contracts for coverage details, including specific drug lists, reimbursement rates, and any limitations on pharmacies or hospitals [4]. - Understanding the reimbursement process for innovative drugs is crucial, as it often involves specific purchasing locations, prescriptions from specialists, and prior authorization from insurance companies [4]. - Consumers should balance the cost of premiums with the level of coverage provided, considering personal health conditions and financial capabilities when deciding on insurance products that include innovative drug coverage [5].

Core Viewpoint - The commercial health insurance sector is currently in a phase of "selecting from a menu," with significant potential for innovation as the market approaches a trillion yuan scale. The year 2025 is anticipated to be a pivotal year for commercial health insurance, marked by the release of an innovative drug directory and regulatory encouragement for the development of insurance products for individuals with pre-existing conditions [1] Group 1: Commercial Health Insurance Development - The 2025 National Medical Security Work Conference emphasized the support for the development of commercial health insurance, placing it as a priority in establishing a multi-tiered medical security system [1] - The conference called for the integration of commercial health insurance with basic medical insurance, encouraging the inclusion of reasonable medical expenses outside the basic insurance directory and promoting investment in innovative drugs [1][3] - The market is expected to shift from a focus on rapid growth to a more structured approach that addresses the diverse needs of the elderly and individuals with pre-existing conditions [1] Group 2: Innovative Drug Directory - The first version of the commercial health insurance innovative drug directory includes only 19 types of drugs, primarily for specific clinical uses with clear reimbursement rules [4] - Concerns remain regarding the implementation of this directory, particularly whether the listed drugs can be easily accessed in hospitals and whether negotiated discount prices can translate into higher reimbursement rates [5][6] - The directory aims to facilitate the entry of high-value innovative drugs into public hospitals, enhancing the synergy between commercial health insurance and basic medical insurance [3][5] Group 3: Role of Commercial Health Insurance in Clinical Pathways - There is an expectation for commercial health insurance to play a more active role in optimizing clinical pathways for patients, moving from a passive reimbursement model to influencing treatment decisions [7] - The integration of innovative drugs into the insurance payment framework is seen as a way to enhance the insurance sector's influence on healthcare practices [7][10] - The need for collaboration with healthcare providers and access to clinical data is crucial for commercial insurers to effectively manage costs and improve patient outcomes [10][11] Group 4: Market Innovations and Trends - The aging population is driving demand for innovative health insurance products, with a focus on integrating group and individual health insurance models [12][13] - The concept of "personal account-based long-term medical insurance" is emerging, which combines long-term medical coverage with savings features, potentially addressing the challenges posed by an aging society [13][15] - Employers can benefit from this innovative model by attracting and retaining employees while facilitating their long-term health savings [14][15]

Core Insights - The introduction of the commercial health insurance innovative drug directory aims to address the mismatch between high-cost innovative drugs and patient affordability, particularly in the context of rare diseases and cancer treatments [1][2][3] Group 1: Policy Developments - The National Medical Insurance Administration announced the establishment of a commercial health insurance innovative drug directory, which will include 19 drugs, including CAR-T therapies and treatments for rare diseases [1][2] - The directory is designed to complement the basic medical insurance system, allowing for a multi-tiered medical security framework that supports the development of commercial health insurance [2][3] - The commercial health insurance innovative drug directory is expected to serve as a transitional pool for innovative drugs, allowing them to be included in commercial insurance before potentially entering the basic medical insurance system [2][14] Group 2: Drug Inclusion and Pricing - Five CAR-T products have been included in the commercial health insurance innovative drug directory, which has been a focal point in recent negotiations due to their high costs [2][4][5] - The pricing negotiations for these drugs have reportedly been more favorable than those for basic medical insurance, with some products achieving significant price reductions [5][8] - The directory aims to reduce the financial burden on patients, potentially saving them hundreds of thousands of yuan in out-of-pocket expenses for treatments like CAR-T [6][7] Group 3: Challenges and Considerations - The implementation of the commercial health insurance innovative drug directory faces challenges, including the need for coordination among stakeholders, data integration, and collaboration between medical institutions and payment systems [3][10][13] - The effectiveness of the directory in providing access to patients will depend on the efficiency of medical institutions in adopting these drugs, as inclusion in the directory does not guarantee availability in hospitals [13][15] - The sustainability of this new mechanism relies on the risk management capabilities of commercial insurance providers and the effective integration of commercial and basic medical insurance systems [15] Group 4: Market Opportunities - The establishment of the commercial health insurance innovative drug directory opens significant market opportunities for commercial health insurance, particularly in designing specialized insurance products for high-value innovative drugs [3][12] - The directory is expected to enhance the clinical use of innovative drugs and improve the overall return on investment in research and development for pharmaceutical companies [15][16] - The introduction of this directory aligns with the broader goal of expanding the health service industry in China, with projections indicating a total scale of 16 trillion yuan by 2030 [3]

Core Viewpoint - The introduction of the commercial health insurance innovative drug directory marks a substantial phase of collaboration between medical insurance and commercial insurance, opening a market-oriented payment channel and enhancing the accessibility of innovative drugs [1][21]. Group 1: Policy and Implementation - The national medical insurance bureau has added a commercial health insurance innovative drug directory, which includes 19 drugs, effective from January 1, 2026 [2][23]. - The directory focuses on highly innovative drugs with significant clinical value that exceed the basic medical insurance coverage, aiming to complement the basic insurance system [2][23]. - The commercial health insurance innovative drug directory is expected to serve as a "transition pool" for innovative drugs, allowing them to first enter the commercial insurance directory before considering inclusion in the basic medical insurance [3][36]. Group 2: Drug Inclusion and Impact - Notable drugs included in the directory are five CAR-T products, which have been a focal point in previous medical insurance negotiations due to their high costs, often exceeding one million yuan [2][25]. - The inclusion of CAR-T products is anticipated to significantly reduce the out-of-pocket expenses for patients, potentially saving them hundreds of thousands of yuan [7][27]. - The directory also includes treatments for rare diseases and high-profile conditions like Alzheimer's disease, reflecting a commitment to support vulnerable patient groups [8][28]. Group 3: Challenges and Considerations - The implementation of the commercial health insurance innovative drug directory faces challenges such as balancing the interests of pharmaceutical companies, insurance costs, and patient accessibility [3][24]. - There is a need for improved data integration and actuarial foundations to support long-term efficacy data and claims risk models for innovative drugs [3][24]. - The collaboration between medical institutions and payment systems requires breakthroughs to ensure the effective entry of directory drugs into hospitals [3][24]. Group 4: Market Opportunities - The launch of the commercial health insurance innovative drug directory opens significant market opportunities for commercial health insurance, with a focus on designing specialized insurance products for high-value innovative drugs [4][24]. - The directory is expected to enhance the clinical medication level and overall research return rates in the industry, particularly benefiting leading innovative pharmaceutical companies [20][37]. - The mechanism is seen as a step towards a multi-layered and collaborative medical insurance system in China, although its long-term sustainability will depend on effective risk management by commercial insurance institutions [19][36].

撤回"官宣"，公司回应 "官宣！复星联合健康保险9款医疗险覆盖商保创新药！"12月18日，北京商报记者了解到，复星联合健 康保险的一则公告在行业引起关注。 多天前，首版《商业健康保险创新药品目录》公布，目录中19种创新药被正式推向了商业健康保险的舞 台中央。业内正翘首以待，谁会将目录中的创新药纳入保险保障，成为第一批"吃螃蟹"的保险机构。一 则"官宣！复星联合健康保险9款医疗险覆盖商保创新药！"的推文便在保险圈炸开了锅。 然而，市场情绪的升温尚未持续太久，便出现了异样。12月18日，北京商报记者注意到，这篇承载着行 业期待的"官宣"文章，在其官方微信公众号上已然不见踪影，只留下"已删除"的提示。一场备受瞩目 的"官宣"，在众目睽睽之下上演了"撤回"的戏码。那么，从高调宣布到悄然撤回，这"虚晃一枪"的背 后，原因几何？对于整个健康险市场而言，首版商保创新药目录的发布，究竟意味着怎样的机遇与变 局？ "此前部分城市的惠民保宣传纳入商保创新药目录中的药，目前终于看到有保险公司官宣自家的中端医 疗险、长期医疗险纳入商保创新药目录中的药。"复星联合健康保险的官宣无疑令业内欣喜。 在中央财经大学副教授刘春生看来，将商保创 ...

Core Viewpoint - The announcement by Fosun United Health Insurance regarding the inclusion of nine medical insurance products covering commercial health insurance innovative drugs was retracted shortly after its release, raising questions about the internal decision-making process and the implications for the health insurance market [1][2][4]. Group 1: Announcement and Withdrawal - Fosun United Health Insurance initially announced that nine of its medical insurance products would cover innovative drugs listed in the newly released commercial health insurance innovative drug directory [1][3]. - The announcement was later deleted from their official WeChat account, with the company stating that the decision to retract was due to ongoing discussions and lack of finalization on the product details [2][3]. Group 2: Market Implications - The release of the commercial health insurance innovative drug directory, which includes 19 high-value innovative drugs, is seen as a potential opportunity to enhance the purchasing rate of commercial insurance [5]. - The inclusion of innovative drugs in medical insurance is viewed as a necessary direction for health insurance development, aiming to alleviate patients' financial burdens and improve product competitiveness [6]. Group 3: Financial Performance and Capitalization - Fosun United Health Insurance reported a net profit of 0.63 billion in the first three quarters of the year, continuing a trend of profitability since 2021 [7][8]. - The company has been seeking to increase its registered capital, with a recent approval to raise it from 6.9444 billion to 10.1085 billion, which is expected to enhance its capital strength and support the coverage of innovative drugs [9].

Core Viewpoint - The announcement by Fosun United Health Insurance regarding the inclusion of nine medical insurance products in the commercial health insurance innovative drug directory was retracted shortly after its release, raising questions about the internal decision-making process and the implications for the health insurance market [3][4][6]. Group 1: Announcement and Withdrawal - The initial announcement highlighted that Fosun United Health Insurance would cover nine innovative drugs in its medical insurance products, generating excitement in the industry [3][5]. - The announcement was later deleted from the company's official WeChat account, indicating a lack of finalized discussions regarding the products [4][5]. - The company stated that the adjustment to the drug list would take effect from January 1, 2026, for specific insurance products [5]. Group 2: Market Implications - The release of the first commercial health insurance innovative drug directory, which includes 19 high-value drugs, is seen as a potential opportunity to enhance the purchasing rate of commercial insurance [7]. - The directory aims to address the challenges of high-priced innovative drugs and improve the collaboration between insurance companies and pharmaceutical firms [7][8]. - Experts believe that integrating innovative drugs into medical insurance can significantly reduce patients' financial burdens and enhance the competitiveness of insurance products [6][7]. Group 3: Challenges and Considerations - The main challenges for insurance companies include high drug prices leading to increased claims costs and the lack of historical data for accurate pricing [8][9]. - Companies are encouraged to develop specialized products and collaborate with pharmaceutical companies to create data-sharing and risk-sharing mechanisms [8][9]. - The success of integrating innovative drugs into insurance offerings depends on effective risk management and sustainable business practices [7][9]. Group 4: Company Background and Financial Performance - Fosun United Health Insurance, established in January 2017, is the sixth approved professional health insurance company in China, with major shareholders including Fosun Pharma and the International Finance Corporation [10][14]. - The company has shown a clear upward trend in profitability since 2021, with net profits of 0.20 billion, 0.63 billion, 0.23 billion, and 0.42 billion from 2021 to 2024 [12][13]. - Recent capital increases have been approved, enhancing the company's capital strength and solvency, which is crucial for covering innovative drugs and supporting business expansion [13][14].

Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [2] - The drug Lenvatinib, approved for Langerhans cell histiocytosis, has a high monthly treatment cost of approximately 17,000 yuan, making it unaffordable for many patients [2] - The inclusion of Lenvatinib in the insurance list allows treatment for both Langerhans cell histiocytosis and neurofibromatosis type I in children aged 2 and above, expanding access compared to previous medications [4] Group 2 - The national medical insurance has covered over 50 rare disease types, but there remains a gap compared to the 207 rare diseases listed, due to high costs and lack of available treatments [4] - The introduction of commercial insurance for innovative drugs includes 19 medications, including Lenvatinib, allowing for discounted pricing and reducing the financial burden on families [7] - Initiatives such as the publication of clinical guidelines for 86 rare diseases and the establishment of a national rare disease diagnosis and treatment network are enhancing support for patients [7]

综合多名受访人士的观点，商保目录的发布对于药企、患者、商保等方面均有积极意义。 具体来说，对于患者，商保支付的介入有效解决了高价创新药的支付痛点，让符合条件的患者能够通过 商保获得用药保障，真正实现"好药可及、费用可担"的核心目标；对于药企，目录的落地正式打通了创 新药"医保+商保"双支付格局，为药企开辟了医保之外的核心支付通道，为创新药的商业化落地提供可 持续的支付支撑；而对于险企，目录药品有一定折扣，使商保能够在创新药可及中发挥更积极的多元支 付作用，同时为保司的创新药责任设计提供相对统一的价值参照。 从目录发布到最后实践落地，还需要过不少"关卡"。 "这是一个走向多方共赢的重要起点。"在与第一财经记者谈起刚刚发布的商保创新药目录时，对外经济 贸易大学创新与风险管理研究中心副主任、众托帮联合创始人兼总经理龙格说。 不过，市场和普通民众最为关心的还是在首版《商业健康保险创新药品目录》（2025年）（下称"商保 目录"）发布后，如何能吸引更多险企进行衔接，让目录通过商业健康险真正落地，健康险产品的定价 又是否会有影响。 行业内已有与之衔接的相关产品出现。第一财经记者从市场上了解到，目前惠民保这类普惠型商业健康 ...